{"id":"epoetin-alfa-or-beta","safety":{"commonSideEffects":[{"rate":"2-5%","effect":"Thromboembolism"},{"rate":"10-20%","effect":"Hypertension"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Epoetin alfa and beta are recombinant forms of human erythropoietin, a hormone that promotes the production of red blood cells. They work by binding to the erythropoietin receptor on the surface of erythroid progenitor cells, triggering a signaling cascade that leads to the proliferation and differentiation of these cells into mature red blood cells.","oneSentence":"Epoetin alfa and beta stimulate erythropoiesis by binding to the erythropoietin receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:18.141Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia associated with chemotherapy"}]},"trialDetails":[{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT06520826","phase":"PHASE3","title":"Vafseo Outcomes In-Center Experience","status":"ACTIVE_NOT_RECRUITING","sponsor":"USRC Kidney Research","startDate":"2024-11-20","conditions":"Anemia of Chronic Kidney Disease","enrollment":2200},{"nctId":"NCT00560404","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-04","conditions":"Anemia","enrollment":233},{"nctId":"NCT02988973","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2017-01-12","conditions":"Chronic Kidney Disease","enrollment":334},{"nctId":"NCT06466785","phase":"PHASE3","title":"A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","status":"RECRUITING","sponsor":"Genexine, Inc.","startDate":"2024-01-25","conditions":"Anemia of Chronic Kidney Disease","enrollment":429},{"nctId":"NCT04484857","phase":"PHASE3","title":"Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2020-07-22","conditions":"Anemia Associated With End Stage Renal Disease","enrollment":283},{"nctId":"NCT03552393","phase":"PHASE2","title":"Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-08-03","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":40},{"nctId":"NCT00642967","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-06","conditions":"Anemia","enrollment":127},{"nctId":"NCT00717821","phase":"PHASE3","title":"A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08","conditions":"Anemia","enrollment":421},{"nctId":"NCT02791763","phase":"PHASE3","title":"Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-06","conditions":"Anaemia","enrollment":355},{"nctId":"NCT02145026","phase":"PHASE4","title":"A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-08-06","conditions":"Myelodysplastic Syndromes","enrollment":100},{"nctId":"NCT03408639","phase":"PHASE3","title":"Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2016-06-22","conditions":"Anemia in End-Stage Renal Disease","enrollment":156},{"nctId":"NCT01975818","phase":"PHASE2","title":"Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-10-28","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":201},{"nctId":"NCT02064426","phase":"PHASE2","title":"Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-13","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":88},{"nctId":"NCT00773513","phase":"PHASE4","title":"A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-12-12","conditions":"Chronic Renal Anemia","enrollment":2825},{"nctId":"NCT01519947","phase":"PHASE4","title":"A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-05-30","conditions":"Anemia, Kidney Disease, Chronic","enrollment":87},{"nctId":"NCT00642304","phase":"PHASE3","title":"A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-03-27","conditions":"Anemia","enrollment":20},{"nctId":"NCT00737464","phase":"PHASE4","title":"A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08-26","conditions":"Anemia","enrollment":132},{"nctId":"NCT00661505","phase":"PHASE3","title":"A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05-14","conditions":"Anemia","enrollment":132},{"nctId":"NCT01066000","phase":"PHASE4","title":"A Study for Monthly Methoxy Polyethylene Glycol-Epoetin Beta Treatment in Patients With Chronic Renal Anaemia","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-10-31","conditions":"Anemia","enrollment":33},{"nctId":"NCT02049346","phase":"PHASE4","title":"Comparison Among Erythropoietin Stimulating Agents","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2012-03","conditions":"Anemia of End Stage Renal Disease","enrollment":327},{"nctId":"NCT00717366","phase":"PHASE2","title":"Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-07","conditions":"Renal Anemia","enrollment":64},{"nctId":"NCT00922116","phase":"PHASE4","title":"A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-04-30","conditions":"Anemia","enrollment":191},{"nctId":"NCT01342640","phase":"PHASE4","title":"A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-07-18","conditions":"Anemia","enrollment":70},{"nctId":"NCT00776425","phase":"PHASE4","title":"A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-01","conditions":"Anemia","enrollment":117},{"nctId":"NCT00737477","phase":"PHASE3","title":"A Study of Monthly Subcutaneous (SC) Mircera for Maintenance Treatment of Participants With Chronic Kidney Disease on Peritoneal Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-09-30","conditions":"Anemia","enrollment":96},{"nctId":"NCT02238080","phase":"","title":"An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-12","conditions":"Chronic Kidney Diseases","enrollment":197},{"nctId":"NCT01194154","phase":"PHASE2","title":"A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-09-30","conditions":"Kidney Disease, Chronic","enrollment":241},{"nctId":"NCT02767765","phase":"PHASE3","title":"A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-06","conditions":"Anemia","enrollment":61},{"nctId":"NCT00394953","phase":"PHASE3","title":"A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-12","conditions":"Anemia","enrollment":490},{"nctId":"NCT00077610","phase":"PHASE3","title":"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-02","conditions":"Anemia","enrollment":673},{"nctId":"NCT00364832","phase":"PHASE2","title":"A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2001-10","conditions":"Anemia","enrollment":137},{"nctId":"NCT01718379","phase":"PHASE2","title":"Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.","status":"COMPLETED","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2010-07","conditions":"Myelodysplastic Syndromes","enrollment":132},{"nctId":"NCT02608060","phase":"PHASE4","title":"A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2006-09","conditions":"Anemia","enrollment":4},{"nctId":"NCT01309295","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease in Pre-Dialysis or Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-11","conditions":"Anemia, Kidney Disease, Chronic","enrollment":250},{"nctId":"NCT02564094","phase":"PHASE4","title":"A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-02","conditions":"Anemia","enrollment":54},{"nctId":"NCT00081484","phase":"PHASE3","title":"A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Anemia","enrollment":336},{"nctId":"NCT02624141","phase":"PHASE4","title":"A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2006-04","conditions":"Anemia","enrollment":10},{"nctId":"NCT00773331","phase":"PHASE3","title":"A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-07","conditions":"Anemia","enrollment":281},{"nctId":"NCT00559273","phase":"PHASE3","title":"A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-12","conditions":"Renal Anemia, Chronic","enrollment":307},{"nctId":"NCT00077766","phase":"PHASE3","title":"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-03","conditions":"Anemia","enrollment":313},{"nctId":"NCT00882713","phase":"PHASE3","title":"A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-02","conditions":"Anemia","enrollment":202},{"nctId":"NCT00605345","phase":"PHASE3","title":"A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-12","conditions":"Anemia","enrollment":71},{"nctId":"NCT00560547","phase":"PHASE3","title":"A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Anemia","enrollment":""},{"nctId":"NCT00442416","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-02","conditions":"Anemia","enrollment":80},{"nctId":"NCT00327535","phase":"PHASE2","title":"A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-05","conditions":"Anemia","enrollment":153},{"nctId":"NCT00551291","phase":"PHASE2","title":"A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-08","conditions":"Myelodysplastic Syndromes","enrollment":10},{"nctId":"NCT00827021","phase":"PHASE3","title":"The Clinical Evaluation of the Dose of Erythropoietins Trial","status":"COMPLETED","sponsor":"Giovanni FM Strippoli, MD","startDate":"2009-07","conditions":"Kidney Failure, Chronic","enrollment":656},{"nctId":"NCT02827266","phase":"PHASE3","title":"A Study of Epoetin Beta (NeoRecormon) in Anemic Participants With Diabetes and Chronic Renal Failure Who Are Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-10","conditions":"Anemia","enrollment":122},{"nctId":"NCT00545571","phase":"PHASE3","title":"MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Anemia","enrollment":120},{"nctId":"NCT00642850","phase":"PHASE3","title":"STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-11","conditions":"Anemia","enrollment":188},{"nctId":"NCT01695746","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-08","conditions":"Anemia","enrollment":108},{"nctId":"NCT00517881","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of Subcutaneous C.E.R.A. in Pre-Dialysis Participants With Chronic Renal Anemia","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-06","conditions":"Anemia","enrollment":29},{"nctId":"NCT00576303","phase":"PHASE3","title":"A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-04","conditions":"Anemia","enrollment":200},{"nctId":"NCT00077623","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-03","conditions":"Anemia","enrollment":572},{"nctId":"NCT00605293","phase":"PHASE3","title":"A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Anemia","enrollment":101},{"nctId":"NCT00517413","phase":"PHASE3","title":"LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Anemia","enrollment":163},{"nctId":"NCT00699348","phase":"PHASE3","title":"A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-07","conditions":"Anemia","enrollment":351},{"nctId":"NCT00559637","phase":"PHASE3","title":"A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Anemia","enrollment":184},{"nctId":"NCT00773968","phase":"PHASE3","title":"A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-09","conditions":"Anemia","enrollment":140},{"nctId":"NCT00354341","phase":"PHASE3","title":"(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-09","conditions":"Anemia","enrollment":170},{"nctId":"NCT00550680","phase":"PHASE3","title":"A Study of Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Chronic Renal Anemia","enrollment":208},{"nctId":"NCT00413894","phase":"PHASE3","title":"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-03","conditions":"Anemia","enrollment":424},{"nctId":"NCT01156363","phase":"PHASE4","title":"A Study of Monthly Subcutaneous or Intravenous Mircera in Dialysis Patients With Chronic Renal Anaemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-10","conditions":"Anemia","enrollment":86},{"nctId":"NCT00262379","phase":"PHASE3","title":"Use or Non-use of Epoetin Beta in Patients Infected by Chronic Hepatitis C","status":"COMPLETED","sponsor":"University Hospital, Angers","startDate":"2005-12","conditions":"Chronic Hepatitis C","enrollment":229},{"nctId":"NCT02232113","phase":"PHASE4","title":"Frequent Dosing of CERA Improves Nutrition and Inflammation in Hemodialysis Patients","status":"COMPLETED","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2012-02","conditions":"Anemia, Inflammation, Malnutrition","enrollment":67},{"nctId":"NCT00662220","phase":"PHASE3","title":"High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4","status":"TERMINATED","sponsor":"Foundation for Liver Research","startDate":"2008-04","conditions":"Chronic Hepatitis C","enrollment":110},{"nctId":"NCT00482716","phase":"PHASE3","title":"Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer","status":"UNKNOWN","sponsor":"St. Bartholomew's Hospital","startDate":"2007-01","conditions":"Anemia, Leukemia, Lymphoma","enrollment":80},{"nctId":"NCT00072059","phase":"PHASE2","title":"Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2003-07","conditions":"Anemia, Lung Cancer","enrollment":""},{"nctId":"NCT00597584","phase":"PHASE3","title":"Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis","status":"COMPLETED","sponsor":"Affymax","startDate":"2007-10","conditions":"Chronic Renal Failure, Chronic Kidney Disease, Anemia","enrollment":823},{"nctId":"NCT00434330","phase":"PHASE2","title":"Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis","status":"COMPLETED","sponsor":"Affymax","startDate":"2006-12","conditions":"Anemia, Chronic Kidney Disease, Chronic Renal Failure","enrollment":91},{"nctId":"NCT00830609","phase":"PHASE4","title":"High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3","status":"COMPLETED","sponsor":"Dr. Conrado Fernandez","startDate":"2008-11","conditions":"Chronic Hepatitis C","enrollment":101},{"nctId":"NCT01546337","phase":"","title":"Search for Predictive Markers of Efficacy of ESAs in Patients With Non-myeloid Malignancies or Myelodysplastic Syndrome","status":"TERMINATED","sponsor":"Rennes University Hospital","startDate":"2008-05","conditions":"Myelodysplastic Syndromes, Anemia, Hemopathies","enrollment":30},{"nctId":"NCT00090753","phase":"PHASE3","title":"A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-10","conditions":"Anemia","enrollment":1228},{"nctId":"NCT00442702","phase":"PHASE3","title":"A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-09","conditions":"Anemia","enrollment":228},{"nctId":"NCT00454246","phase":"PHASE3","title":"A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-04","conditions":"Anemia","enrollment":111},{"nctId":"NCT00654992","phase":"PHASE2, PHASE3","title":"Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2006-09","conditions":"Kidney Failure, Acute","enrollment":71},{"nctId":"NCT00433693","phase":"PHASE3","title":"Correction Study of R744 in Renal Anemia Patients on Hemodialysis","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2007-02","conditions":"Hemodialysis Patients","enrollment":50},{"nctId":"NCT00433615","phase":"PHASE3","title":"Clinical Study of R744 to Predialysis Patients","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2007-02","conditions":"Anemia in Pre-Dialysis Patients","enrollment":124},{"nctId":"NCT00491868","phase":"PHASE3","title":"Clinical Study of R744 to Hemodialysis Patients","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2007-06","conditions":"Hemodialysis Patients","enrollment":134},{"nctId":"NCT00492427","phase":"PHASE3","title":"Clinical Study of R744 to Predialysis Patients( Phase III, Comparative Study in Comparison With Epoetin Beta)","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2007-06","conditions":"Predialysis Patients","enrollment":187},{"nctId":"NCT00593801","phase":"NA","title":"Erythropoietin Treatment in Extremely Low Birth Weight Infants","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"1998-05","conditions":"Infant, Low Birth Weight, Anemia","enrollment":219}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1297194,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Epoetin"],"phase":"phase_3","status":"active","brandName":"epoetin alfa or beta","genericName":"epoetin alfa or beta","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epoetin alfa and beta stimulate erythropoiesis by binding to the erythropoietin receptor. Used for Anemia associated with chronic kidney disease, Anemia associated with chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}